Table 2.
Findings from previous series
| Investigator | Treatment modality | Patients (n) | Dose and fractions | Visual outcome (%)
|
Radiologic outcome | Toxicity | Mean follow-up (mo) | ||
|---|---|---|---|---|---|---|---|---|---|
| Improved | Stable | Impaired | |||||||
| Liu et al. (19), 2002 | FCRT | 5 | 45–54 Gy; 1.8 Gy/fraction | 80 | 20 | 0 | Control 100% | 20% (1 transient periorbital edema) | 36 |
| Andrews et al. (5), 2002 | FCRT | 30 | 50–54 Gy; 1.8 Gy/fraction | 30 | 63.3 | 6.7 | Control 100% (decreased in 13%; stable in 87%) | 13% (2 VL, 1 RON, 1 transient OP) | 20.4* |
| Becker et al. (17), 2002 | FCRT | 39 | 54 Gy; 30 (1.8-Gy) fractions | 6 | 94 | 0 | Control 100% (decrease in 2.6%; stable in 97.4%) | 10.3% endocrinologic deficits, 25% erythema in radiation field | 34.8 |
| Narayan et al. (20), 2003 | FCRT | 14 | 50.4–56 Gy; 1.8–2 Gy/fraction | 35.7 | 50 | 14.3 | Control 100% (decreased in 7.1%; stable in 92.9%) | 35.7% (1 RR, 1 transient OP, 1 DE, 2 iritis) | 51.3* |
| Saeed et al. (23), 2003 | FCRT | 6 | 45–55 Gy; 28–30 fractions | 100 | 0 | 0 | Control 100% | 16.6% (1 cataract) | <48 |
| Baumert et al. (16), 2004 | FCRT | 23 | 45–54 Gy; 1.8–2 Gy/fraction | 72.7 | 22.7 | 4.6 | Control 100% (decreased in 4.4%; stable in 95.6%) | 4.6% (1 RR) | 20* |
| Richards et al. (21), 2005 | FCRT | 4 | Mean 43.6 Gy; 26 fractions | 100 | 0 | 0 | Control 100% | 1 radiation-induced hair loss | 30 |
| Landert et al. (18), 2005 | FCRT | 7† | 50–54 Gy; 1.7 or 1.8 Gy/ fraction | 85.7† | 0† | 14.3† | Control 100% | 0% | 57 |
| Sitathanee et al. (23), 2006 | FCRT | 12 | Mean 55.7 Gy; 1.8 Gy/fraction‡ | 60 | 40 | 0 | Control 100%§ | 1 transient VL, 1 vitreous hemorrhage 2 y after RT | 34* |
| Litre et al. (24), 2007 | FCRT | 8 | Mean 45 Gy; 25 (1.8 Gy) fractions | 37.5 | 62.5 | 0 | Control 100% | 0% | 27 |
| Present series, 2009 | FCRT | 9 | Median 51.2 Gy; 1.8–2 Gy/ fraction | 77.8 | 22.2 | 0 | Control 100% (decreased in 22.2%; stable 77.8%) | 22% (1 transient OP, 1 RR) | 98¶ |
Abbreviations: FCRT = functional conformal radiotherapy; VL = visual loss; RON = radiation optic neuropathy; OP = orbital pain; RR = radiation retinopathy; DE = dry eye; RT = radiotherapy.
*
Median, not mean.
†
Number or percentage of eyes, not patients.
‡
One patient was treated with 15-Gy stereotactic radiosurgery.
§
Available for only 50% of patients.
¶
Minimum follow-up of 60 mo.